Forget Bitcoin! I believe this FTSE 100 growth stock could help you retire wealthy

Roland Head highlights a FTSE 100 (INDEXFTSE: UKX) newcomer he’d buy for a retirement portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The Bitcoin price has fallen by nearly 40% since peaking at more than £10,000 in July. What will happen next? To be honest, I’ve no idea. Although I admire the blockchain technology that lies behind this cryptocurrency, I don’t see a long-term future for Bitcoin itself.

These crypto-coins aren’t easily used for payment and aren’t recognised as a currency anywhere in the world. Bitcoin doesn’t have any asset backing either. So its value is completely speculative and based solely on the balance of supply and demand.

It all seems very risky to me. Call me old-fashioned, but I prefer to invest my cash into real businesses that generate cash profits and growth. So here I’m going to highlight two growth stocks I’d be happy to buy and hold until I retire.

A FTSE 100 newcomer

Hikma Pharmaceuticals (LSE: HIK) hasn’t been in the FTSE 100 for very long. But this £4.8bn company has a track record of growth. This suggests to me its place in the big-cap index should be quite safe.

The group specialises in producing generic versions of popular medicines and also sells its own range of branded products. Hikma’s two main markets are the US and the Middle East & North Africa.

Growth has been strong in recent years — sales have risen from $1,365m to $2,130m since 2013. The shareholder dividend has doubled over the same period, but borrowing levels have remained very low, unlike at some larger pharma groups.

Analysts expect earnings to grow by about 5% in 2020, which seems modest. But I believe Hikma’s 20% operating margin and strong cash generation have the potential to support market-beating growth in the years ahead.

The market shares my view, pricing Hikma stock on 17 times 2020 forecast earnings, with a forecast dividend yield of 1.7%. In my view, buying the shares today should deliver a mix of growth and future income. For investors saving for retirement, I think this could be a good choice.

A future FTSE 100 stock?

With a market-cap of just £1.9bn, FTSE 250 IT services group Softcat (LSE: SCT) has a little way to go before it can be considered for the FTSE 100. But shares in this business have doubled over the last two years and risen by 250% since its flotation in late 2015.

By any measure, the company has been one of the most successful new listings of the last five years. It’s not hard to see why.

Figures released today show revenue rose by 24% to £991.8m during the 12 months to 31 July. Operating profit also rose by 24%, to £84.5m. This shows profit margins are remaining firm despite continued growth — an impressive achievement.

Softcat’s business model as an equipment reseller and service provider doesn’t require much in the way of facilities or capital expenditure. As a result, it’s highly profitable. My sums indicate the group generated a return on capital employed of 73% last year. That means an operating profit of £73 for each £100 invested in the business.

This strong performance has left the shares trading on a demanding 26 times 2020 forecast earnings. This isn’t cheap, and a recession could see orders slow and profits tumble. I’d probably wait for the next market correction to buy more Softcat shares, but I’d be happy to continue holding following today’s results.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals and Softcat. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Retirement Articles

Young Black woman looking concerned while in front of her laptop
Investing Articles

How I’d invest £3 a day in FTSE shares to build passive income of £5,000 a year

Investing just a few pounds in dividend shares each day will build up over time and could generate a passive…

Read more »

Photo of a man going through financial problems
Investing Articles

No savings at 40? I’d buy FTSE 100 stocks at today’s dirt-cheap prices

FTSE 100 stocks are great value right now and offer incredible dividends. If I was 40, I would buy a…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

I’d rather generate passive income from shares than buy-to-let

UK shares generate passive income with a lot less effort than becoming a buy-to-let landlord. And they're much easier to…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

How investing £3 a day could generate passive income of £780 a month

By investing regular monthly sums in FTSE 100 dividend shares I expect to generate a comfortable passive income to fund…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

FTSE 100 shares will give me 4.12% income today and much more tomorrow 

I can already generate an attractive level of dividend income from FTSE 100 shares but this should compound and grow…

Read more »

Asian Indian male white collar worker on wheelchair having video conference with his business partners
Investing Articles

Buy-to-let is in trouble so I’ll generate passive income from shares instead

Buy-to-let is in for a torrid time as interest rates rise and mortgages are pulled. I'll generate a passive income…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

I reckon this week’s dip is a great time to buy UK passive income stocks

Today's volatile markets are handing me a great opportunity to expand my portfolio of passive income stocks at reduced valuations.

Read more »

Middle-aged black male working at home desk
Investing Articles

Here’s how much I’d need to invest to earn passive income of £1,000 a month

Investing in shares is a great way of building a passive income. So how much should I put away each…

Read more »